Peptide Comparison
CJC-1295 + Ipamorelin vs Tesamorelin + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| CJC-1295 + Ipamorelin | Tesamorelin + Ipamorelin | |
|---|---|---|
| Class | GHRH analog + selective GHRP blend (GH-secretagogue stack) | FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). | Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. |
| Route | SC injection | SC injection |
| Half-life | CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs | Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs |
| Dosage (research) | 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off | 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off |
| Evidence tier | Anecdotal + Animal Studies | FDA-Approved (component) |
| Research depth | 5 indexed | — |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication | Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 + Ipamorelin or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CJC-1295 + Ipamorelin and Tesamorelin + Ipamorelin?
CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack); Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm); Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: CJC-1295 + Ipamorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.
Which has stronger evidence, CJC-1295 + Ipamorelin or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.
Which is more accessible, CJC-1295 + Ipamorelin or Tesamorelin + Ipamorelin?
Neither CJC-1295 + Ipamorelin nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: CJC-1295 + Ipamorelin, Compounding Restricted; Tesamorelin + Ipamorelin, Compounding Restricted.
Are CJC-1295 + Ipamorelin and Tesamorelin + Ipamorelin ever combined?
CJC-1295 + Ipamorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…